Clinical Immunology

Clinical Immunology

Homeopathic Materia Medica Of Clinical Immunology

The vision of Physiological Regulating Medicine on the use of physiological low doses of Hormones, Cytokines, Neuropeptides and Growth Factors


JERÔME MALZAC

Physiological Regulating Medicine is based on a revolutionary idea in the medical field: restoring the initial physiological conditions of a sick body by using the same biological molecules that are usually present in the body and which control and guide its functions in healthy conditions.

To be precise, these molecules are very well known and extensively studied in Molecular Biology, and it is no mere chance that they are called messenger molecules – substances that can convey the “right instructions” for correct function to the various cells of the body.

These molecules include Neuropeptides (Nervous System messengers), hormones (Endocrine System messengers), cytokines (Immune System messengers).

There are also growth factors, which are essential tissue regulating and stimulating molecules. It has been acknowledged that these substances play a decisive role in determining either health or disease, and today it has been ascertained that every disease is the expression of changes in concentrations – either of an increase or of a reduction – of these substances. All international medical research is focusing on the study of messenger molecules; the positive (healing) or negative (disease) fate of several pathological conditions depends on them and on the possibility of using them for therapeutic purposes.

Every disease is the expression and consequence of changes in messenger molecule concentrations

JERÔME MALZAC

For instance, correcting Immune System alterations through the use of cytokines and en- docrine diseases with hormones is one of the most fascinating and innovative objectives of research centered on applying Molecular Biology to Medicine. But the clinical application of this know-how has always come to a standstill when faced with the side effects caused by the high doses of these substances that have been routinely used until today.

The pharmaceutical technique known as SKA (Sequential Kinetic Activation) enables the administration of LOW DOSES OF HORMONES, NEUROPEPTIDES, CYTOKINES AND GROWTH FACTORS to achieve the same therapeutic results as high doses but without any side effects.

SKA (Sequential Kinetic Activation)

It is a sophisticated DRUG DELIVERY SYSTEM that ensures efficacy of molecular concentrations below the minimal effective dose.

In November 2009 the prestigious international scientific review Pulmonary Pharmacology & Therapeutics [22 (2009) 497-510] published the article Low dose oral administration of cytokines for treatment of allergic asthma. The paper enlarged on the effects of low doses of SKA-activated cytokines in the treatment of allergic asthma, proving in a clear, evident and especially reproducible manner that the low doses administered during the study produced the same effects as high doses in changing a series of clinical and laboratory parameters typical of the allergic condition. 

The SKA Method opens a new era in options for the clinical use of messenger molecules and concretises the “scientific dream” of using biological molecules, such as cytokines, hormones and neuropeptides, in low doses (the only doses that can avoid side effects).

A new frontier has most likely been set for pharmaceutical industries and in the field of Molecular Biology, and both Italian researchers and the Italian industry are paving the way in this sector.

Cytokines

Low physiological doses of cytokines activated with the SKA procedure are marketed in a hydroalcoholic solution in 30 ml bottles. The drug concentration is in picograms/ml, which corresponds to a homeopathic dilution of 4CH1.

DIRECTIONS 

The standard posology is 20 drops twice a day. Sublingual administration is recommended.

THERAPEUTIC PROTOCOLS

The duration of therapy differs depending on the clinical condition and on the gravity of the disease.

Chronic diseases usually require the administration of treatment cycles with minimum du- ration of 2 months. They can be repeated, preferably after a 15-day suspension.

In acute diseases therapy is continued until remission of symptoms. At times a massive dose therapy can be applied with 10 drops every 20 minutes for maximum 2 hours.

THERAPEUTIC STRATEGY

Cytokines can be prescribed following two trends.

 According to an aetiological decisional process:

  • if the pathological condition is the expression of a down-regulation (deficiency) of a certain cytokine, the same cytokine will be used;
  • if the pathological condition is the expression of an up-regulation (excess) of a certain cytokine, the so-called “opposing cytokine” will be used.

 According to a symptomatological decisional process:

  • the cytokine is prescribed to suit the symptoms of the patient.

PRESCRIPTION ACCORDING TO THE AETIOLOGICAL DECISIONAL PROCESS

CYTOKINESTRENGTHENING same cytokineMODULATION opposing cytokine
Anti IL-1 alphaAnti IL-1 alpha 4 CHIL-1 4CH
Anti IL-1 betaAnti IL-1 beta 4 CHIL-1 4CH
GCSFGCSF 4CHIL-10 4CH / IL-4 4CH
IL-1IL-1 4CHAnti IL-1 alpha 4CH Anti IL-1 beta / IL-10 4CH
IL-2IL-2 4CHIL-11 4CH
IL-3IL-3 4CHIL-10 4CH
IL-4IL-4 4CHINF-gamma 4CH / IL-12 4CH
IL-5IL-5 4CHTGF-beta 4CH
 IL-6 IL-6 4CHAcute inflammation:IL-4 4CH/INF-γ 4CHChronic inflammation:TNF Alpha 4CH
IL-7IL-7 4CHIL-10 4CH / TGF-beta 1 4CH
IL-8IL-8 4CHIL-10 4CH / TGF-beta 1 4CH
IL-9IL-9 4CHIL-10 4CH
IL-10IL-10 4CHIL-1 4CH / TNF 4CH IL-6 4CH
IL-11IL-11 4CHIL-2 4CH
IL-12IL-12 4CHIL-4 4CH/IL-10 4CH
INF alphaINF alpha 4CHIL-4 4CH
INF gammaINF gamma 4CHIL-4 4CH
TGF-beta 1TGF-beta 4CHIL-12 4CH
TNFTNF-alpha 4CHAnti IL-1 4CH+IL-10 4CH

Prescription according to the symptomatological decision process




HORMONES & NEUROPEPTIDES

Low physiological doses of hormones activated with the SKA procedure are marketed in a hydroalcoholic solution in 30 ml bottles. The drug concentration is in picograms/ml, which corresponds to the homeopathic dilution of 4CH for some (Beta-Endorphin, Melatonin, Somatostatin), and in nanograms/ml, corresponding to the homeopathic dilution of 6DH for others.

DIRECTIONS

The standard posology is 20 drops twice a day. Sublingual administration is recommended.

THERAPEUTIC PROTOCOLS

The duration of treatment differs depending on the clinical condition and on the gravity of the disease.

Chronic diseases usually require the administration of treatment cycles with minimum du- ration of 2 months. They can be repeated, preferably after a 15-day suspension.

In acute diseases therapy is continued until remission of symptoms. At times a massive dose therapy can be applied with 10 drops every 20 minutes for maximum 2 hours.

THERAPEUTIC STRATEGY

Hormones and neuropeptides can be prescribed following two trends.

According to an aetiological decisional process:

  • if the pathological condition is the expression of a down-regulation (deficiency) of a certain hormone or neuropeptide, the same hormone will be used;
  • If the pathological condition is the expression of an up-regulation (excess) of a certain hormone, the so-called “opposing hormone” will be used consistently with the physiology of negative feedback.

According to a symptomatological decisional process:

  • the hormone is prescribed to suit the symptoms of the patient.

PRESCRIPTION ACCORDING TO THE AETIOLOGICAL DECISIONAL PROCESS

HORMONESTRENGTHENING same hormoneMODULATION opposing hormone
ACTHACTH 6DHTSH 6DH
Beta-ENDORPHINBeta-ENDORPHIN 4CHno opposing hormone
Beta-ESTRADIOLbeta-ESTRADIOL 6DHPROGESTERON 6DH
CALCITONINCALCITONIN 6DHPARATHYROID HORMONE 6DH
DOPAMINDOPAMIN 6DHSEROTONIN 6DH MELATONIN 4CH PROLACTIN 6DH
FSHFSH 6DHbeta-ESTRADIOL 6DH
GHIGF-1 6DHSOMATOSTATIN 4CH
LHLH 6DHPROGESTERON 6DH
MELATONINMELATONIN 4CHPROLACTIN 6DH
OXYTOCINOXYTOCIN 6DHPROGESTERONE 6DH Beta-ESTRADIOL 6DH
PARATHYROID HORMONEPARATHYROID HORMONE 6DHCALCITONIN 6DH
PROGESTERONEPROGESTERONE 6DHBeta-ESTRADIOL 6DH
PROLACTINPROLACTIN 6DHMELATONIN 4CH
SOMATOSTATINSOMATOSTATIN 4CHIGF-1 6DH PROLACTIN 6DH
T3T3 6DHSOMATOSTATIN 4CH
T4T4 6DHSOMATOSTATIN 4CH
TSHTSH 6DHACTH 6DH SOMATOSTATIN 4CH

Prescription according to the symptomatological decision process


GROWTH FACTORS

Low physiological doses of growth factors activated with the SKA procedure are marketed in a hydroalcoholic solution of 30 ml bottles. The drug concentration is in picograms/ml, which corresponds to a homeopathic dilution of 4CH.

DIRECTIONS 

The standard posology is 20 drops twice a day. Sublingual administration is recommended.

THERAPEUTIC PROTOCOLS 

The duration of therapy differs depending on the clinical condition and on the gravity of the disease.

Chronic diseases usually require the administration of treatment cycles with minimum du- ration of 2 months. They can be repeated, preferably after a 15-day suspension.

In acute diseases therapy is continued until remission of symptoms. At times a massive dose therapy can be applied with 10 drops every 20 minutes for maximum 2 hours.

THERAPEUTIC STRATEGY

Growth factors can be prescribed following two trends.

According to an aetiological decisional process:

  • if the pathological condition is the expression of a down-regulation (deficiency) of a certain growth factor, the same growth factor will be used.

According to a symptomatological decisional process:

  • the growth factor is prescribed to suit the symptoms of the patient.

Prescription according to the symptomatological decision process




MATERIA MEDICA

Abdominal pain (cramp-like)INTERLEUKIN-5 4CH
Abdominal swellingINTERLEUKIN-11 4CH
Acute and chronic stressINTERLEUKIN-8 4CH
Acute inflammatory diseasesAnti INTERLEUKIN-1alpha 4CH / Anti INTERLEUKIN-1beta 4CH
AgingINTERLEUKIN-2 4CH / FGF 4CH / IGF-1 4CH / PDGF 4CH / ACTH 6DH / Beta-ESTRADIOL 6DH / FSH 6DH / LH 6DH
Allergic syndromesINF-gamma 4CH+INTERLEUKIN-12 4CH
AllergiesINTERLEUKIN-12 4CH + INTERFERON-gamma 4CH / INTERLEUKIN-13 4CH
Allergy-induced hyperlacrimationINTERLEUKIN-12 4CH
Appetite disorders (excessive appetite)INTERLEUKIN-1 beta 4CH / INTERLEUKIN-6 4CH
Appetite controlCNTF 4CH
Articular painINF-alpha 4CH
Articular symptoms (painful-degenerative) with limited movementFGF 4CH
AstheniaINTERLEUKIN-1 beta 4CH / INTERLEUKIN-7 4CH / INF-alpha 4CH / INF-gamma 4CH / ACTH 6DH / PARATHYROID HORMONE 6DH
Asthenia and drowsinessINTERLEUKIN-9 4CH
AutismBDNF 4CH
Autoimmune diseasesTGF-beta 1 4CH
Basic regulation in patients undergoing immunotherapyINTERLEUKIN-11 4CH
Basic therapy for autoimmune diseasesINTERLEUKIN-4 4CH
Blurred vision with scintillating scotomasEGF 4CH
Bone painCALCITONIN 6DH
Bruise-induced painINTERLEUKIN-5 4CH
Burning sensation in the mouthINTERLEUKIN-2 4CH
CatarrhINTERLEUKIN-8 4CH
Cerebral agingBDNF 4CH / CNTF 4CH
Chapped skinEGF 4CH
Chemotaxis activationINTERLEUKIN-8 4CH
Chronic bacterial infectionsTNF-alpha 4CH
Chronic catarrhINTERLEUKIN-9 4CH
Chronic fatigue syndromeDOPAMIN 6DH
Chronic inflammationsTGF-beta 1 4CH
Chronic inflammatory diseasesINTERLEUKIN-4 4CH / INTERLEUKIN-10 4CH
Chronic pain syndromesINTERLEUKIN -10 4CH / Beta-ENDORFINA 4CH / TGF-beta 1 4CH
Chronic viral infectionsINF-gamma 4CH
Chronic stressACTH 6DH
Cicatrisation difficultyFGF 4CH
Circadian rhythm and organ function alterationsMELATONIN 4CH CNS and PNS diseases NT3 4CH / NT4 4CH
Complementary treatment for tumoursSOMATOSTATIN 4CH / INTERLEUKIN-12 4CH / INTERFERON-gamma 4CH / INTERLEUKIN-2 4CH / MELATONIN 4CH / TNF-alpha 4CH
Confusion at night with sleep disordersTNF-alpha 4CH
Constipation and flatulenceINTERLEUKIN-5 4CH 
Cramp-like painPARATHYROID HORMONE 6DH
Crohn’s DiseaseINTERLEUKIN-10 4CH + Anti IL-1
Damage to the myelin sheathG1 4CH
Decreased sexual arousalDOPAMIN 6DH
Decreased sexual satisfactionOXYTOCIN 6DH
Diet disordersSEROTONIN 6DH
Digestive disordersINTERLEUKIN-3 4CH
Drud addictionDOPAMIN 6DH
Early agingINTERLEUKIN-3 4CH
Erratic painINTERLEUKIN-3 4CH
Erythroid proliferation disorders (synergy with erythropoietin)INTERLEUKIN-9 4CH
Feeling of heaviness in the epigastrium with sorenessEGF 4CH
Female hormone cycle disorders and infertilityBeta-ESTRADIOL 6DH / FSH 6DH / LH 6DH / PROGESTERON 6DH
FeverAnti IL-1 4CH
Food intolerancesINTERLEUKIN-12 4CH
Gastric acid hypersecretionEGF 4CH
General sicknessINTERLEUKIN-2 4CH / INTERLEUKIN-6 4CH
Growth and development disordersINTERLEUKIN-7 4CH / INTERLEUKIN-11 4CH
Growth disordersIGF-1 4CH / T4 6DH
HeadacheSEROTONIN 6DH
Haemopoiesis disordersINTERLEUKIN-3 4CH / INTERLEUKIN-11 4CH
Hypersensitivity to painEGF 4CH
HyperparasympathicotoniaACTH 6DH
HypersympathicotoniaMELATONIN 4CH
HyperthyroidismSOMATOSTATIN 4CH
HypothyroidismT3 6DH
Hot flushesBeta-ESTRADIOL 6DH
Immune response triggered in chronic and autoimmune diseasesGCSF 4CH
ImmunodeficienciesINTERLEUKIN-2 4CH
Intermenstrual spottingPROGESTERON 6DH
Intestinal parasitosisINTERLEUKIN-5 4CH
ItchingEGF 4CH
Itching and burning sensationINTERLEUKIN-10 4CH
Jet lagMELATONIN 4CH
Lack of attentivenessDOPAMIN 6DH
Lack of sexual desireDOPAMIN 6DH
Localised inflammationsINTERLEUKIN-2 4CH
Loss of appetiteACTH 6DH
Loss of strength in limbs, easy tirednessNGF 4CH
Low female libidoFSH 6DH / OXYTOCIN 6DH / DOPAMIN 6DH
Low male libidoLH 6DH / DOPAMIN 6DH
Memory disordersNGF 4CH / IGF-1 4CH (stimulates hippocampus function) / INTERLEUKIN-11 4CH
Memory lossINTERLEUKIN-3 4CH
Menstrual painPROGESTERON 6DH
Mental fatigueINTERLEUKIN-4 4CH
Mental strainDOPAMIN 6DH
Mental tirednessBDNF 4CH / G1 4CH
Mood disordersNGF 4CH / NT3 4CH / NT4 4CH / OXYTOCIN 6DH / DOPAMIN 6DH
Mood disorders and unstable moodMELATONIN 4CH / SEROTONIN 6DH / TRYPTOPHAN 6DH
Muscle weaknessG1 4CH / NT3 4CH / NT4 4CH / PROLACTIN 6DH
Myalgia and sti fness especially in the morningTNF-alpha 4CH
Mytogenic activityPDGF 4CH
Nasal obstruction and nose itchINTERLEUKIN-12 4CH
Nervous breakdown and tirednessINTERLEUKIN-7 4CH / INTERLEUKIN-11 4CH
Neuralgic painNGF 4CH / INTERLEUKIN-9 4CH
NeuroastheniaT4 6DH / TSH 6DH
Neurological damage (during development or subsequent to injuries)BDNF 4CH / CNTF 4CH / NT3 4CH / NT4 4CH
OsteoporosisCALCITONIN 6DH
Outcome of psychic shockBDNF 4CH
Ovarian polycystosisFSH 6DH / PROGESTERON 6DH
Pain of diverse originsBeta-ENDORPHIN 4CH
Pain syndromesBeta-ENDORPHIN 4CH / Anti INTERLEUKIN-1 4CH / NT4 4CH
Painful muscular spasmsINF-alpha 4CH
Paroxysmal sneezingINTERLEUKIN-12 4CH
Physical astheniaT4 6DH
Pulsating painINTERLEUKIN-7 4CH / INTERLEUKIN-11 4CH
Premenstrual syndromePROGESTERON 6DH / Beta-ENDORPHIN 4CH
Productive coughINTERLEUKIN-8 4CH
PsoriasisINTERLEUKIN-11 4CH / INTERLEUKIN-4 4CH / INTERLEUKIN-10 4CH
Pyrosis and gastric acid hypersecretion INTERLEUKIN-11 4CH
Recurrent infectionsINTERLEUKIN-7 4CH
Recurrent nighttime coughINTERLEUKIN-12 4CH
Recurrent viral infectionsINF-alpha 4CH
Red mucous membranesINTERLEUKIN-10 4CH RRI with IgA deficiency INTERLEUKIN-5 4CH
Sadness and loss of interestNGF 4CH
Sagging skinBeta-ESTRADIOL 6DH
Sensitivity to infectious diseasesGCSF 4CH
Sensitivity to viral infectionsINTERLEUKIN-2 4CH
Side effects of chemotherapy, radiotherapy and antiviral treatmentsINTERLEUKIN-3 4CH
Sight disordersCNTF 4CH
Skin eruptionsINTERLEUKIN-3 4CH
Skin agingEGF 4CH / FGF 4CH
Skin rashesEGF 4CH
Skin thinning and ulcersNGF 4CH
Sleep disordersMELATONIN 4CH / TRIPTOPHAN 6DH / INTERLEUKIN-1 beta 4CH
Social phobiaOXYTOCIN 6DH
Spastic cramp-like painINTERLEUKIN-4 4CH
Spastic muscle painINF-gamma 4CH
Stiff musclesBDNF 4CH
StressBDNF 4CH / Beta-ESTRADIOL 6DH / MELATONIN 4CH
Subacute pain syndromesINTERLEUKIN-2 4CH / Beta-ENDORPHIN 4CH
Sudden pain with numbingINF-alpha 4CH
Supportive treatment during deliveryOXYTOCIN 6DH
Supportive treatment of AutismOXYTOCIN 6DH
Supportive therapy of Pakinson’s diseaseDOPAMIN 6DH
Swollen and reddened skinINTERLEUKIN-12 4CH
Tendency toward overweightT3 6DH
Tingling sensation and numbness in hands and feetBDNF 4CH
Vertigo with vomitingINTERLEUKIN-3 4CH
Vomiting – loss of appetiteINTERLEUKIN-10 4CH
Water retentionINTERLEUKIN-9 4CH / TSH 6DH
Weariness, adynamiaINTERLEUKIN-2 4CH
WrinklesPDGF 4CH